GlaxoSmithKline (NYSE: GSK) will build its first new manufacturing plant in the United Kingdom in 40 years, the drug giant disclosed Thursday.

Through an investment of $794 million, GSK says it will create some 1,000 jobs.

The new production plant will be built in Scotland, and two other GSK facilities will be upgraded.

GSK also said “further significant investment” in additional manufacturing based in the U.K. is “under consideration.”

The decision came after the U.K. government created a “patent box” that will result in lower taxes on products created in that country. GSK Chief Executive Andrew Witty had lobbied hard for the changes and said that the company could add jobs in the U.K. if the changes were made.

In 209, Witty threatened to move jobs out of the U.K. if changes weren’t made in tax policy.

“The patent box is exactly the sort of active, long-term and creative support that we need from the Government to ensure that the UK remains an attractive place for highly skilled sectors such as pharmaceuticals,” Witty said in a statement. (Read more here.)

In 2010, the government initiated plans for the “patent box.”

Said Witty at the time: “When implemented, the patent box has the potential to transform the way in which the UK is viewed by companies such as GSK as a location for new investments in high added-value R&D and manufacturing.” GSK pledged to invest $780 million in new facilities. (Read details here.)

[GSK ARCHIVE: Check out years of GSK stories as reported in WRAL Tech Wire by clicking here.]

On Thursday, Witty fulfilled that pledge.

“The introduction of the patent box has transformed the way in which we view the U.K. as a location for new investments, ensuring that the medicines of the future will not only be discovered, but can also continue to be made here in Britain,” Witty said in a statement.

“Consequently, we can confirm that we will build GSK’s first new U.K. factory for almost 40 years and that we will make other substantial capital investments in our British manufacturing base. In total, this will create up to 1,000 new jobs over the lifetime of the projects.

“We are also actively considering other investments in our UK manufacturing network which would create further jobs and reinforce the UK’s international competitiveness and as a world leader in life sciences,” he added.

GSK operates its U.S. headquarters in RTP.

Read the full announcement here.